Exact FDA event identifier

Event 95817

6 recalled-product records grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: November 19, 2024
Product types: Drug
Classifications: Class II
Statuses: Ongoing
Recalling firm wording: Mylan Institutional, Inc.

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

6 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 6

Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-442-20

D-0131-2025

Recall number: D-0131-2025
Initiated: November 19, 2024
Classification: Class II
Status: Ongoing
Recalling firm: Mylan Institutional, Inc.
Quantity: 2,835 cartons

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent and Superpotent Drug

Code information

Lot #: 3115936, Exp. Date 07/2025

Distribution pattern

Nationwide in the USA.

drug · product 2 of 6

Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-039-20

D-0132-2025

Recall number: D-0132-2025
Initiated: November 19, 2024
Classification: Class II
Status: Ongoing
Recalling firm: Mylan Institutional, Inc.
Quantity: 988 cartons

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent and Superpotent Drug

Code information

Lot #: 3115707, Exp. Date 02/2025

Distribution pattern

Nationwide in the USA.

drug · product 3 of 6

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-443-20

D-0133-2025

Recall number: D-0133-2025
Initiated: November 19, 2024
Classification: Class II
Status: Ongoing
Recalling firm: Mylan Institutional, Inc.
Quantity: 1,664 cartons

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent and Superpotent Drug

Code information

Lot #: 3115893, Exp. Date 6/2025

Distribution pattern

Nationwide in the USA.

drug · product 4 of 6

Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-041-20

D-0134-2025

Recall number: D-0134-2025
Initiated: November 19, 2024
Classification: Class II
Status: Ongoing
Recalling firm: Mylan Institutional, Inc.
Quantity: 1,133 cartons

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent and Superpotent Drug

Code information

Lot #: 3115448, Exp. Date 12/31/2024;3115732, Exp. Date 3/31/2025; 3116024, Exp. Date 9/30/2025

Distribution pattern

Nationwide in the USA.

drug · product 5 of 6

Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-445-20

D-0135-2025

Recall number: D-0135-2025
Initiated: November 19, 2024
Classification: Class II
Status: Ongoing
Recalling firm: Mylan Institutional, Inc.
Quantity: 690 cartons

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent and Superpotent Drug

Code information

Lot #: 3115924, Exp. Date 06/2025

Distribution pattern

Nationwide in the USA.

drug · product 6 of 6

Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-040-20

D-0136-2025

Recall number: D-0136-2025
Initiated: November 19, 2024
Classification: Class II
Status: Ongoing
Recalling firm: Mylan Institutional, Inc.
Quantity: 205 cartons

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent and Superpotent Drug

Code information

Lot #: 3115869, Exp. Date 03/2025

Distribution pattern

Nationwide in the USA.